| 汪 涛,吕遐智,王 萍,胡 玥,胡传朋.紫杉醇联合卡铂治疗卵巢癌的临床疗效及对患者血清CA125、CA199、CEA水平的影响[J].现代生物医学进展英文版,2018,(18):3596-3600. |
| 紫杉醇联合卡铂治疗卵巢癌的临床疗效及对患者血清CA125、CA199、CEA水平的影响 |
| Curative Effect of Paclitaxel Combined with Carboplatin in the Treatment of Ovarian Cancer and the Effects on the Serum CA125, CA199 and CEA Levels |
| Received:May 31, 2018 Revised:June 24, 2018 |
| DOI：10.13241/j.cnki.pmb.2018.18.045 |
| 中文关键词: 卵巢癌 紫杉醇 卡铂 糖类抗原125 糖类抗原199 癌胚抗原 |
| 英文关键词: Ovarian cancer Paclitaxel Carboplatin Saccharide antigen 125 Glycogen antigen 199 Carcinoembryonic antigen |
| 基金项目:安徽省自然科学基金项目(1508085MH196) |
|
| Hits: 590 |
| Download times: 271 |
| 中文摘要: |
| 摘要 目的：分析紫杉醇联合卡铂治疗卵巢癌的临床疗效及对患者血清糖类抗原125(CA125)、糖类抗原199(CA199)、癌胚抗原(CEA)水平的影响。方法：选择我院2014年1月~2016年12月收治的41例卵巢癌患者，按随机数字表法分为对照组(n=20)和研究组(n=21)。对照组给予紫杉醇联合顺铂治疗，研究组给予紫杉醇联合卡铂治疗。比较两组临床疗效，治疗前后血清CA125、CA199、CEA水平、卡氏评分的变化，不良反应的发生情况和生存情况。结果：治疗后，研究组总有效率显著高于对照组(P<0.05)；两组血清CA125、CA199及CEA水平均较治疗前明显下降，且研究组低于对照组(P<0.05)；研究组卡氏评分改善率高于对照组(P<0.05)，胃肠道反应、神经毒性损伤、骨髓抑制及血液系统毒性率反应发生率低于对照组(P<0.05)；两组1年生存率及中位生存期比较差异无统计学意义(P>0.05)。结论：紫杉醇联合卡铂治疗卵巢癌的疗效明显优于紫杉醇联合顺铂治疗，其能够降低患者血清CA125、CA199及CEA水平，改善患者生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the curative effect of paclitaxel combined with carboplatin in the treatment of ovarian cancer and the effect on the serum carbohydrate antigen 125 (CA125), carbohydrate antigen 199 (CA199) and carcinoembryonic antigen (CEA) levels. Methods: 41 cases of ovarian cancer patients admitted in our hospital from January 2014 to January 2016 were selected and divided into the control group (n=20) and the research group (n=21) according to random number table method. The control group was treated byh paclitaxel combined with cisplatin, and the research group was treated by paclitaxel combined with carboplatin. Then the curative ef- fect, changes of serum levels of CA125, CA199 and CEA, karst scores before and after treatment, incidence of side effects and survival were compared between two groups. Results: After treatment, the total effective rate of research group was higher than that of the control group(P<0.05). The serum levels of CA125, CA199 and CEA of both groups were decreased than those before treatment, which were ob- viously lower in the research group than those of the control group(P<0.05). The karst score improvement rate of research group was higher than that of the control group (P<0.05), while the incidence rates of gastrointestinal reaction, neurotoxic injury, bone marrow inhi- bition and blood system toxicity in research group were lower than those in the control group(P<0.05). No significant difference was found in the 2-year survival rate and median survival time between two groups(P>0.05). Conclusion: Paclitaxel combined with carbo- platin is more effective than paclitaxel combined with cisplatin in the treatment of ovarian cancer, it can effectively reduce the serum levels of CA125, CA199 and CEA, improve the quality of life of patients. |
|
View Full Text
View/Add Comment Download reader |
| Close |
